Interleukin-27
IL27proteinIL-27 exerts immunomodulatory and cardioprotective effects that suppress inflammatory responses in atherosclerosis and myocardial injury.
Pathway placement
Cascade stepPlaque inflammation
Confidencelow
RationaleImmunomodulatory, cardioprotective cytokine; plaque-specific mechanisms incompletely characterized.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000197272
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I43
C — confounder / Type-II70
A — assay feasibility68
E — evidence strength26
T1DI (composite)7
Specificity differential (R−C)-26.9
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- The Role of Interleukin-27 in Atherosclerosis: A Contemporary Review.Cardiology · 2021 · PMID 34010834 · doi